Review article

Evolution and current state of assays for measuring parathyroid hormone

Mario Skugor ; Endocrine and Metabolic Institute and Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
Manjula Gupta ; Endocrine and Metabolic Institute and Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
Sankar D. Navaneethan ; Endocrine and Metabolic Institute and Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA

Abstract

Development of the assays for parathyroid hormone (PTH) stems from the early radioimmunoassay development. Recognition of the assay shortcomings led to the development of the newer immunometric assays (IMA) that allowed for better characterization and understanding of the PTH molecule secretion, action and metabolism. Newer assays also allowed for reliable diagnosis of primary hyperparathyroidism and hypoparathyroidism in the majority of the patients. However, despite apparent improvements in the assay's characteristics, considerable difficulties remain in assessment of the bone metabolism in the patients with end stage renal disease. Combining the results of second generation PTH IMA assays with third generation PTH IMA assays or standardizing the PTH results may offer further enhancement in the ability to assess bone metabolism in these patients, but further studies are necessary to elucidate their true clinical value.

Keywords

parathyroid hormone; immunometric assay; kidney disease

Hrčak ID:

53365

URI

https://hrcak.srce.hr/53365

Publication date:

4.6.2010.

Visits: 1.520 *